Stimuli‐responsive delivery of therapeutics for diabetes treatment

Abstract

Diabetic therapeutics, including insulin and glucagon‐like peptide 1 (GLP‐1), are essential for diabetic patients to regulate blood glucose levels. However, conventional treatments that are based on subcutaneous injections are often associated with poor glucose control and a lack of patient compliance. In this review, we focus on the different stimuli‐responsive systems to deliver therapeutics for diabetes treatment to improve patient comfort and prevent complications. Specifically, the pH‐responsive systems for oral drug delivery are introduced first. Then, the closed‐loop glucose‐responsive systems are summarized based on different glucose‐responsive moieties, including glucose oxidase, glucose binding protein, and phenylboronic acid. Finally, the on‐demand delivery systems activated by external remote triggers are also discussed. We conclude by discussing advantages and limitations of current strategies, as well as future opportunities and challenges in this area.